Customer Service: 866-788-9007

Customer Service: 866-788-9007

Customer Service: 866-788-9007

Chris Otte

Castle Biosciences to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum

Friendswood, TX – November 2, 2017 Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO will be presenting at Canaccord Genuity’s 2017 Medical Technologies & Diagnostics Forum on Thursday, November 9th, 2017 at 1:30 p.m. ET in New York City. About Castle Biosciences …

Castle Biosciences to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum Read More »

Watch the Replay of Federico Monzon, MD’s Presentation Webcast at the Cancer Research & Oncology Live Virtual Event

Catch the on-demand replay of “Personalizing Melanoma Management with Molecular Diagnostics” presented by Castle Biosciences’ Federico Monzon, MD. The presentation provides an overview of the use of molecular diagnostics in melanoma, from screening to monitoring therapy, and was part of a virtual event that focused on advancements in prevention, diagnosis and treatment of different cancer …

Watch the Replay of Federico Monzon, MD’s Presentation Webcast at the Cancer Research & Oncology Live Virtual Event Read More »

New Publication Highlights First Prospective Performance Assessment of the DecisionDx-Melanoma Gene Expression Profile Test

Friendswood, TX – September 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of the first prospective assessment of prognostic performance for the DecisionDx®-Melanoma test in a multi-center population of patients with cutaneous (skin) melanoma. The gene expression profile (GEP) test uses tumor biology …

New Publication Highlights First Prospective Performance Assessment of the DecisionDx-Melanoma Gene Expression Profile Test Read More »

Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated in Newly Expanded Multicenter Cohort of 782 Patients

Friendswood, TX–August 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that results of the DecisionDx®-Melanoma prognostic test’s performance in a cumulative cohort of 782 patients with cutaneous melanoma were presented during the 23rd International Pigment Cell Conference (IPCC 2017) held in Denver, CO from August …

Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated in Newly Expanded Multicenter Cohort of 782 Patients Read More »

New Publication Confirms Analytic Validity of Castle Biosciences’ DecisionDx-UM Test for Uveal Melanoma in its Clinical Laboratory

Friendswood, TX – August 10, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a study confirming the robust, reproducible performance characteristics of the DecisionDx®-UM test, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. …

New Publication Confirms Analytic Validity of Castle Biosciences’ DecisionDx-UM Test for Uveal Melanoma in its Clinical Laboratory Read More »

Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies

Friendswood, TX – July 18, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced three important milestones in improving access to DecisionDx®-UM, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. Palmetto GBA, the administrator of the MolDX® …

Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies Read More »

Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma

Chicago, IL – June 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that three abstracts detailing results from studies of DecisionDx®-Melanoma were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6. Presentations included an …

Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma Read More »

Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions

Friendswood, TX – May 15, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma. The test uses tumor biology to provide an individual risk of recurrence in cutaneous …

Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions Read More »

Oxford Finance and Silicon Valley Bank Close $20 Million Credit Facility with Castle Biosciences

ALEXANDRIA, Va. and SANTA CLARA, Calif. and FRIENDSWOOD, Texas.– May 9, 2017 – Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, and Silicon Valley Bank, the bank of the world’s most innovative companies and their investors, today announced the closing of a $20 million …

Oxford Finance and Silicon Valley Bank Close $20 Million Credit Facility with Castle Biosciences Read More »

Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma

Friendswood, TX – May 1, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the prognostic accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in a cohort of patients with head and neck melanoma. Results demonstrated that the DecisionDx-Melanoma test accurately …

Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma Read More »